Latest Schedule 13G passive stakes

Janus Henderson Group Ltd. has disclosed a beneficial ownership of 7.3% of Dyne Therapeutics Inc.'s common stock as of June 30, 2026.

Janus Henderson Group Ltd. has disclosed a beneficial ownership of 7.3% of Dyne Therapeutics Inc.'s common stock as of June 30, 2026.

Janus Henderson Group Ltd. has updated its beneficial ownership filing for Protara Therapeutics, Inc., reporting a 8.4% stake as of June 30, 2026.

Janus Henderson Group Ltd. has updated its beneficial ownership filing for Protara Therapeutics, Inc., reporting a 8.4% stake as of June 30, 2026.

Canadian Imperial Bank of Commerce has updated its beneficial ownership filing for Flutter Entertainment plc, now holding 7.3% of the common stock.

Canadian Imperial Bank of Commerce has updated its beneficial ownership filing for Flutter Entertainment plc, now holding 7.3% of the common stock.

Janus Henderson Group Ltd. has filed a Schedule 13G, reporting beneficial ownership of 3,587,806 shares, representing 9.7% of Ziff Davis, Inc.'s common stock.

Janus Henderson Group Ltd. has filed a Schedule 13G, reporting beneficial ownership of 3,587,806 shares, representing 9.7% of Ziff Davis, Inc.'s common stock.

Janus Henderson Group Ltd. has amended its Schedule 13G filing, reporting a decrease in its beneficial ownership of ICU Medical, Inc. common stock to 11.1%.

Janus Henderson Group Ltd. has amended its Schedule 13G filing, reporting a decrease in its beneficial ownership of ICU Medical, Inc. common stock to 11.1%.

Janus Henderson Group Ltd. has disclosed beneficial ownership of 9,783,192 shares, representing 14.0% of Immix Biopharma, Inc.'s common stock, through various asset managers.

Janus Henderson Group Ltd. has disclosed beneficial ownership of 9,783,192 shares, representing 14.0% of Immix Biopharma, Inc.'s common stock, through various asset managers.

Janus Henderson Group Ltd. has updated its Schedule 13G filing to report a 0.3% beneficial ownership stake in Janux Therapeutics, Inc., indicating no change in control or significant strategic involvement.

Janus Henderson Group Ltd. has updated its Schedule 13G filing to report a 0.3% beneficial ownership stake in Janux Therapeutics, Inc., indicating no change in control or significant strategic involvement.

Janus Henderson Group Ltd. has filed a Schedule 13G, disclosing a beneficial ownership of 3.8% in Flex Ltd. ordinary shares as of June 30, 2026.

Janus Henderson Group Ltd. has filed a Schedule 13G, disclosing a beneficial ownership of 3.8% in Flex Ltd. ordinary shares as of June 30, 2026.

Janus Henderson Group Ltd. has disclosed beneficial ownership of 4.8% of Bicara Therapeutics Inc. common stock, as of June 30, 2026.

Janus Henderson Group Ltd. has disclosed beneficial ownership of 4.8% of Bicara Therapeutics Inc. common stock, as of June 30, 2026.

Janus Henderson Group Ltd. has filed a Schedule 13G, reporting beneficial ownership of 590,030 shares, representing 4.8% of Bel Fuse Inc.'s Class B Common Stock.

Janus Henderson Group Ltd. has filed a Schedule 13G, reporting beneficial ownership of 590,030 shares, representing 4.8% of Bel Fuse Inc.'s Class B Common Stock.

Janus Henderson Group Ltd. has disclosed a beneficial ownership of 3.0% in Ocugen, Inc., holding 10,000,000 shares and warrants.

Janus Henderson Group Ltd. has disclosed a beneficial ownership of 3.0% in Ocugen, Inc., holding 10,000,000 shares and warrants.

A filing reveals Ayrton Capital LLC, Alto Opportunity Master Fund, SPC, and Waqas Khatri collectively hold a 2.93% stake in Enveric Biosciences, Inc. through warrant exercises.

Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri have collectively acquired a significant 8.78% stake in Sunation Energy, Inc., signaling institutional confidence.

A filing reveals that Ayrton Capital LLC, Alto Opportunity Master Fund, SPC, and Waqas Khatri collectively hold a 5.26% stake in China Natural Resources Inc., acquired through warrants.

Janus Henderson Group Ltd. has disclosed beneficial ownership of 5.1% of Revolution Medicines, Inc. common stock as of June 30, 2026.

Janus Henderson Group Ltd. has disclosed beneficial ownership of 5.1% of Revolution Medicines, Inc. common stock as of June 30, 2026.

Janus Henderson Group Ltd. has updated its beneficial ownership filing for Achieve Life Sciences, Inc., reporting a 5.4% stake.

Janus Henderson Group Ltd. has updated its beneficial ownership filing for Achieve Life Sciences, Inc., reporting a 5.4% stake.

Janus Henderson Group Ltd. has reported beneficial ownership of 5.0% of Inspired Entertainment, Inc.'s common stock as of June 30, 2026, through various managed portfolios.